The number of child casualties presumably linked to the usage of DOK-1MAX syrup reached 19 in Uzbekistan, as a one-year-old child died in the Kashkadarya region on Wednesday (December 28), the regional Prosecutor's Office reports.
The child had taken the DOK-1MAX syrup manufactured by Indian 'Marion Biotech' for five days. On December 27, the child’s health condition deteriorated. On the same day, the baby was hospitalized in the Kashkadarya regional branch of the Republican Scientific Emergency Medical Center. The minor died on the following day.
Tablets and syrups are withdrawn from sale in all pharmacies across the Central Asian republic in the prescribed manner.
The Karshi City Prosecutor’s Office has filed a criminal case under Article 186-3 of the Criminal Code. A preliminary investigation is underway.
India's Central Drugs Standard Control Organization (SDSCO) reported on Thursday (December 29) that it had inspected Marion Biotech's production facility and pledged more action based on the probe report. The SDSCO reviewed the company's Noida facility in the Uttar Pradesh state and is in regular touch with its Uzbekistan counterpart, the Indian health authority said in a statement.
‘The samples of the cough syrup have been taken from the manufacturing premises and sent to Regional Drugs Testing Laboratory, Chandigarh for testing,’ the message reads.
The Geneva-based World Health Organisation (WHO) informed that it is in constant contact with Uzbekistan's health authorities and is ready to assist in further investigations.
More on this subject:
18 child casualties registered presumably as side effect of DOK-1MAX
Health Ministry: DOK-1MAX syrup contains ethylene glycol
Comments (0)